Dr. van der Heijde has served as a consultant to, and has received speaking fees and/or honoraria (less than $10,000 each) from Abbott, Amgen, Bristol-Myers Squibb, Centocor, Merck, Schering-Plough, UCB, and Wyeth.
Rheumatoid Arthritis Clinical Studies
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis†
Article first published online: 29 NOV 2007
Copyright © 2007 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 56, Issue 12, pages 3928–3939, December 2007
How to Cite
van der Heijde, D., Klareskog, L., Landewé, R., Bruyn, G. A. W., Cantagrel, A., Durez, P., Herrero-Beaumont, G., Molad, Y., Codreanu, C., Valentini, G., Zahora, R., Pedersen, R., MacPeek, D., Wajdula, J. and Fatenejad, S. (2007), Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis & Rheumatism, 56: 3928–3939. doi: 10.1002/art.23141
ClinicalTrials.gov identifier: NCT00393471.
- Issue published online: 29 NOV 2007
- Article first published online: 29 NOV 2007
- Manuscript Accepted: 7 SEP 2007
- Manuscript Received: 19 DEC 2006
- Wyeth Pharmaceuticals, Collegeville, PA
- European Agency for the Evaluation of Medicinal Products
- 3Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54: 1063–74., , , , , , et al.
- 5Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35–45., , , , , , et al.
- 8The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26–37., , , , , , et al.
- 22Etanercept combined with methotrexate is well tolerated for 3 years: results from the trial of etanercept and methotrexate with radiographic and patient outcomes (TEMPO). Poster number SAT0196. Presented at the Annual European Congress of Rheumatology, June 21–24, 2006, Amsterdam, The Netherlands., , , , .
- 25Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006; 54: 3119–25., , , , .